GMNN and neoplasm: As the HR pathway is only active after DNA double-strand breaks in proliferating cells, we evaluated RAD51 IHC after the exclusion of low-γH2AX (DNA damage marker)- or low-geminin (G2/S phase marker)-expressing tumor samples.